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Background: The anatomy of PFO suggests that it can allow thrombi and potentially harmful circulatory factors to
travel directly from the venous to the arterial circulation – altering circulatory phenotype. Our previous publication
using high-resolution LC-MS/MS to profile protein and peptide expression patterns in plasma showed that albumin
was relatively increased in donor samples from PFO-related than other types of ischemic strokes. Since albumin
binds a host of molecules and acts as a carrier for lipoproteins, small molecules and drugs, we decided to investigate the
albumin-bound proteins (in a similar sample cohort) in an effort to unravel biological changes and potentially discover
biomarkers related to PFO-related stroke and PFO endovascular closure.
Methods: The method used in this study combined albumin immuno-enrichment with high resolution LC-MS in order
to specifically capture and quantify the albumin-bound proteins. Subsequently, we measured cholesterol and HDL in a
larger, separate cohort of PFO stroke patients, pre and post closure.
Results: The results demonstrated that a number of proteins were specifically associated with albumin in samples with
and without endovascular closure of the PFO, and that the protein profiles were very different. Eight proteins, typically
associated with HDL were common to both sample sets and quantitatively differently abundant. Pathway analysis of the
MS results suggested that enhanced cholesterol efflux and reduced lipid oxidation were associated with PFO closure.
Measurement of total cholesterol and HDL in a larger cohort of PFO closure samples using a colorimetric assay was
consistent with the proteomic predictions.
Conclusions: The collective data presented in this study demonstrate that analysis of albumin-bound proteins could
provide a valuable tool for biomarker discovery on the effects of PFO endovascular closure. In addition, the results
suggest that PFO endovascular closure can potentially have effects on HDL, cholesterol and albumin-bound
ApoA-I abundance, therefore possibly providing benefits in cardioprotective functions.
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Patent Foramen Ovale (PFO), a congenital cardiac ab-
normality where the left and right atria of the heart are
connected, is highly prevalent (25%-30%) in the general
population [1]. PFO’s caused more than 250,000 strokes
in the United States, allowing peripheral embolisms to
travel directly to the brain and are also associated with
debilitating migraine headaches [2]. Emerging studies
show that PFO-related neurovascular disease is a multi-
organ condition with varying individual risk factors that
may require individualized therapeutic approaches -
opening the field for new pharmacologic and therapeutic
targets such as PFO endovascular closure [1].
Although in asymptomatic patients PFO is not neces-
sarily considered a disease, the full effects of this congeni-
tal abnormality on health are not clear. Clinical trials to
investigate treatment options for ischemic stroke, includ-
ing PFO endovascular closure are ongoing, but because in-
dividual risks vary, and treatments may need to be tailored
to each individual patient, controversies regarding PFO
and PFO closure persist. In part, we believe this is due to a
poor understanding of the molecular landscape of PFO-
related neurovascular injury. Endovascular closure of PFO
provides a rare bedside model in which to study the effects
of a specific mechanical intervention on circulatory pro-
tein signaling, both immediately and over time [3,4].
Clinical proteomics is an ideal and promising approach
for uncovering the changes in complex multi-organ dis-
eases in PFO-related disease since PFO allows for un-
known, but potentially harmful and vasoactive mediators
to travel directly to the brain triggering stroke, unrelenting
migraine and altering circulatory phenotype in blood [3].
Our previous publication using high-resolution LC-
MS/MS to profile protein expression patterns in plasma
demonstrated a collection of differently abundant proteins,
including albumin and ApoA1, before and 12 months after
stroke related PFO closure [4]. In a recent publication in-
vestigating the association of serum albumin concentra-
tions and ischemic strokes [5], the authors found a
significant association between low serum albumin levels
and, in particular cardioembolic and cryptogenic infarc-
tions suggesting PFO might be a factor.
It is well known that albumin has pleiotropic functions
including maintenance of plasma oncotic pressure, bind-
ing a host of toxic molecules and acting as a carrier for
lipoproteins, small molecules and drugs [6-10]. Many
previous publications have proposed that low abundance
biomarkers for many diseases may be associated with al-
bumin since binding to albumin extends the half-life of
smaller proteins and protein fragments that may other-
wise be rapidly cleared by the kidneys [11-15]. In fact,
the likelihood that key biomarkers may exist in blood
mainly bound to albumin has potentially confounded
the success of many plasma or serum-based biomarkerdiscovery studies, since albumin and other abundant
protein depletion strategies have been implemented
in an effort to reduce the large dynamic range of these
fluids [16].
Although ApoAI (the major component of HDL) and
HDL are the well documented mediators of cholesterol
efflux [17-19], recent studies have shown that albumin
also mediates cholesterol efflux from cultured fibroblasts
and endothelial cells [20-22] but the mechanism is not
known.
Albumin is also actively being tested in clinical trials
as a treatment for acute brain injury [23,24]. In light of
these and our prior findings, characterization of albumin-
bound proteins with respect to physiological changes could
potentially be paradigm changing.
In the current study, we present data suggesting that
albumin-bound proteins may be related to biological
and physiological changes associated with PFO closure.
To demonstrate this, we returned to the same sample
set from the previous study and applied immunoenrich-
ment coupled to mass spectrometry to capture and
quantify albumin-bound proteins at baseline and 3–12
month follow up after stroke–related PFO, with and
without endovascular closure [4]. Subsequently, we mea-
sured cholesterol and HDL in a larger, separate cohort
of PFO stroke patients, pre and post closure. Based on
our proteomic findings and pathway analysis predictions,
we wanted to investigate if albumin-bound proteomic




Plasma samples were obtained from PFO stroke patients
and healthy controls with similar risk factors from
the Cardio-Neurology Clinic of Massachusetts General
Hospital in accordance with IRB approval. PFO related
“cryptogenic ischemic strokes” were identified by two
vascular board certified neurologists. Rigorous inclusion/
exclusion criteria were applied to ensure proper diagnosis
in each group, and all patients underwent the following
testing to rule out other etiology related to ischemic em-
bolic infarct: 1) physical exam by a vascular neurologist
to document clinical syndrome consistent with ischemic
infarct; 2) MRI/MRA and CTA to document ischemic in-
farct and to rule out other reasons of infarct such as
intracranial stenosis, large vessel occlusion, dissection;
3) transthoracic and/or transesophageal echocardiogram
to assess and document the presence of PFO and rule
out atrial/ventricular thrombus or any valvular lesions
that may be related to embolism; 4) extended cardiac
monitoring to rule out atrial fibrillation or other cardiac
arrhythmia. In addition other ischemic stroke sub-
types such as lacunar infarct related to hypertension and
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cluded. All patients with active infection, active pregnancy,
or renal/liver failure which may alter protein signaling
profiles and those with absence of baseline imaging such
as CT or MRI needed to confirm clinical stroke syn-
dromes were excluded. Controls were recruited from sub-
jects with similar baseline risk factors to match the study
population. Subject demographics are listed in Table 1.
Patients were consecutively, prospectively enrolled post
ischemic stroke in accordance with the approval of institu-
tional IRB.
Plasma was obtained in EDTA coated tubes, immedi-
ately processed, aliquoted and frozen within 30 minutes
of collection at −80°C to ensure minimal protein degrad-
ation. Standard operating procedures were strictly ob-
served for all samples. All personnel were trained with
SOP to process samples in the same fashion as follows:
blood was obtained from venous source and immediately
processed (within 5 min) to obtain plasma by centrifuga-
tion at 3400 RPM for 15 minutes at 20°C (to avoid plate-
let activation), removing the plasma supernatant without
disturbing the clot, aliquoted immediately, and frozen
at −80°C.
Samples were carefully transported frozen to be proc-
essed at the same time, in random order, by investigators
blinded to the clinical data to avoid bias and batch
variations.
MSIA immuno-enrichment of albumin-bound proteins
Custom MSIA tips activated with polyclonal anti-albumin
or anti-betalactoglobulin antibodies were obtained from
Thermo Fisher Scientific. All samples were processed with
both anti-albumin and anti-betalactoglobulin tips using aTable 1 PFO stroke patient characteristics in separate
validation cohort (n = 104)
Patient characteristics (n = 104)





Coronary artery disease 7 (6.73%)
Migraine 31 (29.81%)
Current smoker 17 (16.35%)
Alcohol 43 (41.35%)




Pre-closure 60 (57.69%) Post-closure 69 (66.35%)
All patients had CLIO certified cholesterol and HDL measured pre and post
PFO closure at the same time interval as the exploratory cohort.Versette Automated Liquid Handler (Thermo Fisher
Scientific) as previously described [25]. Specifically, the
MSIA-Tips were mounted onto the head of the Versette
and initially rinsed with assay buffer (10 mM PBS w/0.1%
TWEEN 20), with 20 cycles (1 cycle consisting of a single
aspiration and dispense of a 100 uL volume), from a single
200 uL buffer aliquot placed in the well of a microplate.
Next, the MSIA-Tips were immersed into the wells of the
microplate containing the samples, and 100 aspirations
and dispense cycles were performed (50 uL volumes each),
allowing for affinity capture of albumin and albumin-
bound proteins. The MSIA-Tips were then rinsed with
assay buffer (25 cycles) from another microplate, and 3
times with water (20 cycles each) from 3 more microplates
(100 uL volumes aspiration and dispenses, from 200 uL
placed in each well). The captured albumin and albumin-
bound proteins were eluted with 33% acetonitrile/
0.4% (v/v) formic acid by aspirating and dispensing a
20 uL volume 200 times, from a total of 50 uL in the wells
of a microplate. The albumin and albumin-bound protein-
containing eluates were then dried down in a SpeedVac
concentrator until dry. Sufficient plasma (1ul or 50–80 ug)
was processed to achieve saturation of the antibody bound
to the MSIA tip resulting in normalization of the albumin
concentration across all samples, and allowing the quanti-
tative comparison of any proteins specifically associated
with albumin. The anti-betalactoglobulin activated tips
were included to control for any non-specific binding to
the anti-albumin antibody since betalactoglobulin is not
present in human plasma (Figure 1).
Preparation of tryptic peptides for MS analysis
After MSIA processing, samples were eluted into a 96
well microplate, lyophilized and processed as previously
described [24]. Briefly, the samples were rehydrated with
25 uL 4 M Urea/300 mM Tris/2.5% n-propanol/10 mM
DTT. Subsequently, 2 uL 500 mM IAA in 1 M NH4CO3
was added. Next, 37.5 uL of 50 mM Tris/5 mM CaCl2
pH 8.0 and 12.5uL of 25 mM Acetic acid/trypsin (20 ug
trypsin + 2.5 mL acetic acid) (Thermo Fisher Scientific).
Samples were incubated at 37°C for 16 h. After digestion,
each sample well was quenched with 3 uL of quench buffer
((333.3 fmol/ul PRTK (Pierce Retention Time Kit)/26.7%
Formic Acid/H2O (Thermo Fisher Scientific), final volume
80 uL)). Twenty uL of each sample were subsequently
injected into the mass spectrometer.
Liquid chromatography and high-resolution mass
spectrometry
Samples were prepared as described above and injected
onto a Thermo Scientific Easy nLC system configured with
a 10 cm × 100 um trap column and a 25 cm × 100 um ID
resolving column. Buffer A was 98% water, 2% metha-
nol, and 0.2% formic acid. Buffer B was 10% water, 10%
Figure 1 Specificity of anti-albumin MSIA enrichment: Binding
characteristics of peptide VQH[Oxid]LGA[A_42]PVT[Phosphoryl]
LRAS[Phosphoryl]YLEIYNEQVR from Kinesin-like protein to
MSIA micro columns activated with either anti-albumin or
anti-beta lactoglobulin, antibodies.
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ples were loaded at 4 uL/min for 10 min, and a gradient
from 0-45% B at 375 nL/min was run over 130 min,
for a total run time of 150 min (including regeneration
and sample loading). The Thermo Scientific LTQ Orbitrap
Velos mass spectrometer was run in a standard Top-10
data-dependent configuration, except that a higher trigger-
threshold (20 K) was used to ensure that the MS2 did
not interfere with the full-scan duty cycle. This ensured
optimal full-scan data for quantification. MS2 fragmen-
tation and analysis were performed in the ion trap mass
analyzer.
MS data analysis
Protein identification was performed using Thermo Scien-
tific Proteome Discoverer version 1.4 (including Sequestand Percolator algorithms). The sequence database used
for the searches was the 040212-RefSeqHuman.fasta. The
Percolator peptide confidence filter was set to “high”. All
Proteome Discoverer search parameters are provided in
Additional file 1 and all identified proteins and pep-
tide sequences are given in Additional file 2. Protein
quantification was performed using Pinpoint version
1.4 software. The Pinpoint quantification workflow in-
cluded importing the Proteome Discoverer .msf files as
spectral libraries. Identified peptides were subsequently
quantified in MS .raw files using the Pinpoint peak find-
ing, chromatographic alignment and area calculation algo-
rithms. Quantified proteins with all related information
are given in Additional file 3. The LC-MS workflow preci-
sion was calculated (within Pinpoint) by quantifica-
tion of the PRTC peptides across all samples yielding
and average CV of 15%. Based on the precision calcula-
tion, differential abundance ratio limits for proteins were
set to >1.2 or <0.8.
Ingenuity pathways (IPA) data analysis
The differential expression results were uploaded and ana-
lyzed using IPA Downstream Effects (Ingenuity© Systems,
www.ingenuity.com) according to the manufacturer’s in-
structions. IPA Downstream Effects attempts to identify
functions that are expected to increase or decrease, given
the observed gene or protein expression changes in the ex-
perimental dataset. Downstream Effects Analysis is based
on expected causal effects between genes or proteins and
functions; the expected causal effects are derived from the
literature compiled in the Ingenuity® Knowledge Base. The
analysis examines genes in the dataset that are known to
affect functions, compares the genes’ direction of change
to expectations derived from the literature, and then issues
a prediction for each function based on the direction of
change in the experimental samples relative to a control. If
the direction of change is consistent with the literature
across most genes, IPA predicts that the function will in-
crease in the experimental sample. If the direction of
change is inconsistent with the literature, IPA predicts that
the function will decrease in the experimental sample and
if the direction of change is not clear (there is no clear pat-
tern related to the literature), IPA does not make a predic-
tion. IPA uses the z-score algorithm to make predictions.
The z-score algorithm is designed to reduce the chance
that random data will generate significant predictions. The
z-score predicts the direction of change for the function.
An absolute z-score of ≥ 2 is considered significant. A bio-
logical function is: increased if the z-score is ≥ 2 and de-
creased if the z-score ≤ -2.
Measurement of cholesterol and HDL
Cholesterol, triglycerides and HDL were measured color-
imetrically on the Cobas c501 chemistry analyzer
Figure 2 Distribution of albumin-bound proteins in PFO closure
vs no-closure sample sets. Specificity for albumin-binding was
assumed when binding to the negative control (anti-BL Ab) was less
than binding to the anti-albumin Ab (ratio <0.5). Eight proteins were
present in both sample sets and their abundance ratios and ROC
AUC scores are given in Table 3. All 8 proteins present in both
sample sets have been previously identified in HDL (26).
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Results
Differential abundance of albumin-bound proteins in
baseline (B) versus 3–12 month follow up (FU) samples
Differential abundance of the albumin-bound proteins
was measured in samples from donors with and without
PFO closure at baseline and at 3–12 month follow-up
(Table 2). The experimental plan was as follows:
1. To compare albumin-bound proteins from samples
taken at baseline (B) and at 3–12 month follow up
(FU). We chose to measure the abundance change
over time as a reflection of the effects of PFO closure
on protein profile during stroke recovery.
2. To obtain protein abundance ratios and ROC scores.
3. To compare results from PFO closure and no-closure
samples.
Albumin coverage was approximately 86% (Additional
file 2). Specificity for albumin-binding was assumed
when binding to the anti-BL Ab was less than binding to
the anti-albumin Ab (ratio of BL to albumin <0.5). In all
measurements, the ratio of albumin itself at baseline (B)
and follow up (FU) samples was ca 1 due to the intentional
saturation of the antibody with sufficient plasma (see
Methods), allowing an accurate measurement of the differ-
ential abundance of proteins specifically bound to albumin.
As described in the methods, the LC-MS workflow preci-
sion was calculated using spiked-in (every sample) heavy
isotope labeled peptides and the average CV was 15%.
Based on the precision calculation, differential abundance
ratio limits for proteins were set to >1.2 or <0.8.
Additional file 4 lists all the albumin-bound proteins
and abundance ratios in PFO closure and no-closure
samples. A total of 46 albumin-bound proteins were de-
tected in PFO closure samples, 15 with an increased ra-
tio (>1.2) and 13 with a decreased ratio (<0.8). Forty
albumin-bound proteins were detected in the PFO no-
closure samples, 9 with an increased ratio (>1.2) and 19
with a decreased ratio (<0.8). Eight proteins were present
in both sample sets (Figure 2), and their abundanceTable 2 Donor sample set processed with immuno-
enrichment and MS for identification and analysis of
albumin-bound proteins
Type of sample Time point n
PFO Closure Baseline 16
PFO Closure 3-12 month Follow Up 5
PFO No Closure Baseline 5
PFO No Closure 3-12 month Follow Up 5ratios and ROC AUC scores are given in Table 3. All 8
proteins present in both sample sets have been previ-
ously identified in HDL [26]. The ROC AUC scores
and abundance ratios of the 8 proteins in common
were very different between the PFO closure and no
closure sample groups. ApoA-1 and ApoC-III had the
highest ROC AUC scores in the closure group indicat-
ing good to excellent classification power between the
baseline and 3–12 month follow up samples, indicating
a significant difference. Abundance ratios (baseline/
follow up) for these proteins were also higher in the PFO
closure sample set than in the no closure sample set, with
the ApoC-III B/FU abundance ratio almost 2× higher in
the closure sample group. In the no closure group, kinin-
ogen had the most significant ROC AUC score and its
abundance ratio was ca 1.6× higher than in the closure
group.
IPA Downstream analysis of albumin-bound proteins
The protein datasets were analyzed by IPA Downstream
Analysis. The IPA biological downstream analysis is
based on z-score and p-value (see Methods). Biological
functions defined in the IPA knowledge database that
are expected to be increased or decreased according to
the protein abundance in the dataset are identified by
the z-score algorithm and the score reflects the signifi-
cance of the prediction (the Z-scores do not measure
the amount of increase or decrease of a function). In our
analyses, the z-score values indicated that a function was
expected to be increased (positive z-score) or decreased
(negative z-score) in PFO closure relative to no-closure
samples. The probability that the association between
the proteins in our datasets and a related biological
Table 3 Abundance ratios and ROC AUC of albumin-bound proteins common to both PFO Closure and No Closure
stroke samples
GI Protein ROC AUC baseline
Closure/Follow up






4557321 apolipoprotein A-I preproprotein [Homo sapiens] 0.950 0.76 1.46 1.26
4557323 apolipoprotein C-III precursor [Homo sapiens] 0.89 0.76 2.00 1.17
19923106 serum paraoxonase/arylesterase 1 precursor
[Homo sapiens]
0.87 0.80 1.69 1.26
4502157 apolipoprotein C-I precursor [Homo sapiens] 0.87 0.52* 0.92 0.9
32483410 vitamin D-binding protein isoform 1 precursor
[Homo sapiens]
0.87 0.80 2.16 1.53
32130518 apolipoprotein C-II precursor [Homo sapiens] 0.84 0.80 0.92 1.35
4504893 kininogen-1 isoform 2 precursor [Homo sapiens] 0.655* 0.92 0.85 1.35
4502149 apolipoprotein A-II preproprotein [Homo sapiens] 0.628* 0.684* 0.92 1.08
*poor classification.
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considered significant if the p-value was ≤0.01 as deter-
mined by using Fisher’s exact T test. The results from
the IPA downstream analysis predicted an increase
(z-score >2.0) in PFO closure vs no-closure in several
functional categories. The most significant function was
cholesterol efflux, with p-values of 2.33E-09, 2.41E-11 in
the PFO closure and no-closure data sets, respectively
and z-scores of 2.73 and 2.37 in the PFO closure and no-
closure data sets, respectively (Figure 3). Conversely, the
analysis predicted a decrease in lipid oxidation with a
z-score of −2.06 and a p-value 1.65E-04 in PFO closure
samples. There was no significant value for decreasedFigure 3 IPA downstream analysis of differently abundant albumin-b
biological function downstream analysis is based on z-score and p-value. In
expected to be increased (positive z-score) or decreased (negative z-score)lipid oxidation in the no-closure samples (Figure 3). This
analysis suggests increased cholesterol and phospholipid
efflux and decreased lipid oxidation in the PFO closure
sample group as compared to the no closure sample
group.
Total cholesterol and HDL levels measured by
colorimetric assay
In order to test the predictions for increased cholesterol
efflux and decreased lipid oxidation resulting from the IPA
analysis described above, we validated total cholesterol and
HDL levels in a separate and larger cohort (n = 104) of
PFO closure patient samples (Table 1) using a standardound proteins in PFO closure vs no-closure sample sets. The IPA
our analyses, the z-score values indicated that a function was
in PFO closure relative to no-closure samples.
Figure 4 HDL and Cholesterol levels measured by colorimetric assay in samples before and after stroke–related PFO closure. HDL and
cholesterol were measured in a separate validation cohort (n = 104, Table 1). All patients had CLIO certified cholesterol and HDL measured pre
and post PFO closure at the same time interval as the exploratory cohort. Conditional logistic regression analysis (Table 4) demonstrated that
cholesterol levels were statistically decreased (p-value 0.0007) and HDL levels were statistically increased (p-value 0.0031) post PFO closure when
compared to baseline levels.
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sults from these measurements were consistent with the
IPA predictions. Cholesterol levels were statistically de-
creased (p-value 0.0007) and conversely, HDL levels were
statistically increased (p-value 0.0031) post PFO closure
compared to baseline levels. We measured HDL in the
samples since in addition to its cardioprotective and
anti-arthrogenic effects, HDL has significant antioxidant
properties [27].
Discussion and conclusions
The anatomy of PFO suggests that, in addition to thrombi,
it can also allow potentially harmful circulatory factors to
travel directly from the venous to the arterial circulation, a
concept important in finding novel therapeutic targets for
PFO-related neurovascular injury [1].
In an effort to unravel biological changes and discover
potential new biomarkers related to PFO endovascular
closure and stroke, we applied immuno-enrichment
and high resolution LC-MS/MS to investigate theTable 4 Conditional logistic regression analysis
Conditional logistic regression analysis
Variables B Odd ratio
(95% confidence interval)
P-value
HDL −0.0567 0.9449 (0.8973, 0.9950) 0.0315
CHOL 0.0214 1.0217 (1.0055, 1.0381) 0.0085
Lipid-lowing Agent −0.8454 0.4294 (0.0850, 2.1695) 0.3064
In the validation cohort, after adjusting for confounders such as lipid lowering
agent, HDL and cholesterol remain (statistically significantly) changed
post-PFO closure.albumin-bound proteins in a small cohort of PFO stroke
patients with and without endovascular closure at baseline
and 3–12 month follow up.
One of the recurring problems with immunoenrich-
ment for protein-protein interaction studies has been
non-specific interactions with capture antibodies, bind-
ing matrices or both [25]. In order to minimize non-
specific interactions, we used MSIA (mass spectrometric
immunoassay) technology which has been demonstrated
to minimize non-specific binding [25,28,29]. In addition,
we developed a negative control with an antibody to a
non-human protein and thus were able to identify and
exclude non-specific interactions.
Our results demonstrated that the MS profiles of
albumin-bound proteins samples from PFO closure vs
no-closure were strikingly different, with only 8 highly
abundant proteins typically found in HDL common to
both sample sets. Biological analysis of the complete
protein data sets using IPA downstream analysis sug-
gested that PFO closure was statistically significantly as-
sociated with increased cholesterol efflux and decreased
lipid oxidation. The protein abundance data also showed
that albumin-bound ApoA-I and several other proteins
were significantly increased (1.2-1.7 fold) and also had
ROC AUC scores (>0.8) in PFO closure (vs no-closure)
donor samples indicating high classification power. To
explore these results further in a separate and larger co-
hort of PFO stroke patients, HDL and cholesterol were
measured using standard clinical methods. These data
showed that HDL was statistically significantly increased
and cholesterol was statistically significantly decreased
following endovascular closure.
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HDL-mediated ApoA-I pathway and passive diffusion
are the only well described pathways for cholesterol ef-
flux [17-19]. However, recent studies [20,21] have shown
that albumin mediates cholesterol efflux in cultured
fibroblasts and endothelial cells but the mechanism is
not known. A study in rats demonstrated that albumin
played a major role in cholesterol transport in circula-
tion, with ca 24% of the nonesterified cholesterol bound
to albumin [30]. Removal of albumin from plasma by
immunoaffinity chromatography reduced total efflux in
cultured fibroblasts by as much as 40% [31] and in a re-
cent study using cultured mouse macrophage cells, the
removal of albumin from plasma resulted in a significant
reduction of cholesterol efflux [21]. The researchers in
the most recent study proposed that albumin may act as
a shuttle to enhance the aqueous diffusion of free chol-
esterol and not take part in a receptor-mediated process.
However, our and others [9] observation that a signifi-
cant amount of ApoA-I is bound to albumin may sug-
gest why albumin is effective in promoting cholesterol
efflux. Since lipid-poor ApoA-I acts as the cholesterol
acceptor in the ABCA1pathway [32], we propose that al-
bumin could be acting as a shuttle to deliver lipid-poor
ApoA-1 to the cell surface, thereby enhancing ABCA1
mediated as well as passive cholesterol efflux. A recent
publication demonstrated that a high percentage of Apo
A-1 recovered from human atheroma is oxidized by
myeloperoxidase and dysfunctional with respect to chol-
esterol efflux [33]. Apo A-1 bound to albumin may be
unavailable to oxidation by myeloperoxidase and there-
fore the high concentration of albumin (>50% of the
total protein) and, as a result, albumin-bound ApoA-I in
human plasma suggests that this proposed mechanism
could be a significant factor in total cholesterol binding
and efflux. In vivo experiments have demonstrated that
analbuminemic patients had decreased ApoA-I and in-
creased free cholesterol (and ApoB) [34]. The reported,
but controversial, protective effects of albumin in cardio-
vascular and cerebrovascular disease [35] may be ex-
plained by the role of albumin in cholesterol efflux.
Whereas little is known about the equilibrium of albumin-
bound and HDL-associated ApoA-I, our preliminary find-
ings are provocative in suggesting that PFO repair may
alter the circulatory composition in stroke patients and
potentially improve the cholesterol profile.
Numerous publications have demonstrated that albu-
min can be a rich source of potential biomarkers as well
as having pleiotropic functions including lipid, drug and
metabolite transport and anti-oxidation [6-8,11-14]. In
our dataset, we identified a collection of low-abundance
proteins and potential biomarkers. Low abundance pro-
teins detected in the albumin-bound fraction of PFO
closure samples (Additional file 4) included receptors(integrin alpha-7 isoform 2 precursor), transcription factors
(HMG box-containing protein 1 isoform 2) and an acyl-
peptide hydrolase (acylamino-acid-releasing enzyme), that
can play an important role in destroying oxidatively dam-
aged proteins in living cells [36]. This finding supports the
hypothesis that low-abundance biomarkers circulating in
blood may exist bound to albumin, preventing their clear-
ance by the kidneys [12].
Proteins with significantly increased abundance ratios
in PFO closure vs no-closure samples included PON 1,
another key component of HDL and partially respon-
sible for its antioxidant and atheroprotective properties
[37], and vitamin D-binding protein. Proteins with de-
creased abundance ratios in PFO closure vs no-closure
samples included kininogen and Apo C-II.
The list of highly abundant albumin-bound proteins
identified in our study is consistent with albumin-bound
proteins identified in previous studies [9,16].
The collective data presented in this study demon-
strate that analysis of albumin-bound proteins could
provide a valuable tool for biomarker discovery on the
effects of PFO endovascular closure. In addition, the
results suggest that PFO endovascular closure can po-
tentially have effects on HDL, cholesterol and albumin-
bound ApoA-I abundance, therefore possibly providing
benefits in cardioprotective functions. The potential
benefit of raising HDL levels has been discussed but re-
mains controversial [38]. However, most experimental
studies have looked at over or under- expression of single
genes and it is clear that a better understanding of the
mechanisms of action and multiple effects of HDL are
needed [39,40].
These findings in this study are provocative, however,
further studies with multiple potential confounders such
as exercise, genetic factors, alcohol, hormonal influences,
and nutrition status (which all affect albumin and lipid
profiles) will be carried out in larger patient cohorts in
future studies.
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